|
-
Announcement
IN3 Medical Device 360° London
Make plans to join us at the Millennium Gloucester Hotel in London this April, for an exceptional medtech investment and partnering event that will feature a full 2 days of start-up company presentations as well as panels, plenary and meet-and-greet sessions focused on the most critical issues impacting the global device industry. More hotel information »
-
 Start-Up Presenters
AiMedics
AiMedics is an Australian innovative medical device company whose mission is to successfully market the world's first non-invasive system which accurately detects and alerts users of sleep-time hypoglycaemia.
-
Anethon
Medical device company developing second-generation biomimetic cardiovascular prostheses, such as blood vessels, patches and heart valves.
-
CellCoTec
A development-stage orthopedics company using Cellular Regeneration Technology (CRT) to provide a single-surgery solution for damaged articular cartilage in the knee.
-
Cortical Dynamics Ltd.
Cortical is a medical device company focused on developing the next generation Brain function monitors by employing the latest theories and technologies to the field.
-
Crospon Ltd.
Crospon, a pioneer in balloon-based intralumenal measurements, is developing valvuloplasty technology which integrates real time diameter measurement to allow valve sizing, annulus distensibility and femoral artery diameter to be easily measured for TAVI procedures.
-
Enox BioPharma
Biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymer based medical devices.
-
Femasys Inc.
An emerging device company developing minimally invasive women's healthcare solutions, including the first device of its kind to allow physicians to quickly and effectively evaluate with ultrasound a woman's fallopian tubes, a critical component of fertility assessment.
-
Glysure
Continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of tight glycemic control and intensive insulin therapy.
-
Implandata Ophthalmic Products
A Germany-based, early-stage, privately held medical device company that has developed a novel technology for 24-hour monitoring of intraocular pressure for the management of glaucoma patients.
-
Michelson Diagnostics Ltd.
Michelson Diagnostics is targeting the skin cancer diagnosis and treatment market with its FDA-cleared VivoSight laser scanner.
-
N8 Medical Inc.
An emerging biomedical technology company focused on creating innovative medical devices and pharmaceuticals to effectively combat a broad spectrum of infectious diseases and microbes, including those attributable to multidrug resistant bacteria.
-
NUUBO
NUUBO's vision is to become the leading provider of cardiopathy diagnosis data for the early detection and accurate diagnosis of cardiac issues.
-
QSTREAM VASCULAR
Developing a full range of cutting-edge endosuturing devices designed to accelerate and simplify total laparoscopic peripheral vascular reconstructions by addressing unmet needs in vascular surgery.
-
Replication Medical, Inc.
Replication Medical develops innovative treatments for degenerative conditions of the spine using our proprietary hydrogel technology.
-
Sapiens Steering Brain Stimulation
Sapiens' high-resolution probe reduces stimulation-induced DBS side-effects for Parkinson patients by steering the stimulation to intended targets only. Sapiens SureSuite products provides image-based planning and programming for optimal DBS therapy.
-
Sirius Implantable System
Sirius develops a self-contained, leadless electrode and an independent miniature pacemaker for the left side of the heart, based on a novel micro-generator that harvests energy from the movement of the heart.
-
Soft Tissue Regeneration Inc.
Has developed and preliminarily tested a potential breakthrough technology for soft tissue regeneration of the anterior cruciate ligament (ACL) of the knee.
-
Specialty Scanners plc
A company with a portfolio of several MRI-compatible products designed to enable the provision of minimally invasive diagnostic and thermal energy (e.g., cryosurgery) treatment procedures under real-time MRI guidance using the company's proprietary Intra-Operative MR Scanner.
-
Vascular Flow Technologies Ltd.
Vascular Flow Technologies Ltd is focused on the research, development and commercialization of vascular devices based on a new understanding of blood flow dynamics - Spiral Laminar Flow (SLF technology).
Current Presenter Count: 20
-
Conference Photos
IN3 Conference Photos
Check Out These Photos From Past IN3 Conferences
-
Future Conferences
New Location!
Orlando, Florida
February 29 - March 2, 2012
The Ritz-Carlton Grande Lakes
Boston, MA / USA
June 27-29, 2012
Hyatt Regency Boston
San Francisco, CA / USA
October 15-17, 2012
Intercontinental Mark Hopkins
Join us in London this Spring and Gain Critical Perspective on the Challenges and Opportunities Facing All Players in the Evolving Global Medical Device Market
Elsevier Business Intelligence, publisher of "The Gray Sheet," IN VIVO, START-UP and MedTech Insight is pleased to announce IN3 Medical Device 360° London.
In today's increasingly complex, globally driven healthcare environment, your business requires up-to-the-minute market expertise on all the critical factors impacting your success. EBI, as a leader in the field of healthcare industry data and analysis, gives medical technology executives a full 360° view of their market, opportunities and challenges. The upcoming IN3 Medical Device 360° London conference - EBI's 46th IN3 event - is a true reflection of this 360° spirit.
Building on the success of past IN³ events in Paris, Rome and Brussels, this must-attend event will bring together start-ups from around the world seeking funding or strategic partnership, along with international industry experts examining the most pressing issues facing our global industry in 2012 and beyond. The two-day program will include corporate and venture capital financing and wireless health venture panels, as well as investor profile presentations and networking sessions.
Program Highlights:
-
Corporate Buy-Side Perspective Panel: What are Buyers Looking for in 2012
In this interactive session, large global device company executives share their insights and perspectives, offering insights on what they like to see from smaller venture-backed companies.
David Cassak, VP of Content, Elsevier Business Intelligence (moderator) Steve Levin, Editor-in-Chief, Elsevier Business Intelligence Arnaud Bernaert, SVP, Corporate Mergers and Acquisitions, Philips Stan Rabinovich, VP, Advanced Technology, Edwards LifeSciences Townsend Goddard, Director, Business Development & Strategic Planning, Stryker Edward Andrle, VP, Business Development & Strategy, Sorin Group Bulend Corbacioglu, VP, Business Development and Licensing, Covidien
Featured Panel: Business Challenges Facing Wireless Health Ventures
This interactive panel consisting of speakers from different sectors of the mobile health ecosystem will explore the challenges facing various wireless health ventures, such as how to secure innovation funding, which mobile health apps and devices face regulation; and how to monetize wireless health by targeting clinicians, payers or consumers.
Victor Higgs, Managing Director, Applied Nanodetectors Ltd. Bleddyn V. Rees, Head of Healthcare, Wragge & Co LLP More panelists to be announced
-
VC Panel Discussion: Raising Venture Capital in Europe: The Best of Times or the Worst of Times?
In this interactive session, investors share their insights and perspectives based on actual company presentations, offering insights on what they like to see from smaller venture-backed companies.
David Cassak, VP of Content, Elsevier Business Intelligence (moderator) Steve Levin, Editor-in-Chief, Elsevier Business Intelligence Alan O'Connell, Partner, Seroba Kernel Life Sciences Aris Constantinides, Investment Director, NBGI Ventures Antoine Papiernik, Managing Partner, Sofinnova Partners
-
Featured Investor Profile Presentations
In these sessions, senior management from key international life sciences investment firms describe their firms' philosophies regarding today's medtech investment climate, what led them to invest in their portfolio companies, and what entrepreneurial companies need to do to secure investment going forward.
|
|